REGENXBIO Inc. (RGNX) – What Are Analysts Saying About This Stock?

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have earned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, nine have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $23.17.

RGNX has been the subject of a number of analyst reports. Mizuho began coverage on shares of REGENXBIO in a research report on Monday, October 5th. They set an “outperform” rating and a $22.00 target price for the company. Morgan Stanley restated an “overweight” rating and set a $18.00 target price on shares of REGENXBIO in a research note on Friday, August 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of REGENXBIO in a report on Friday, September 4th. Barclays downgraded REGENXBIO from an “overweight” rating to a “hold” rating in a report on Friday, August 7th. Finally, Zacks Research upgraded REGENXBIO from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th.

Hedge Funds Weigh In On REGENXBIO

A number of hedge funds have recently bought and sold shares of the business. Versant Capital Management Inc grew its stake in REGENXBIO by 60.4% during the 2nd quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 1,032 shares in the last quarter. Diversified Trust Co boosted its stake in REGENXBIO by 15.9% during the first quarter. Diversified Trust Co now owns 15,499 shares of the biotechnology company’s stock worth $130,000 after buying an additional 2,121 shares during the last quarter. Quantbot Technologies LP acquired a new position in REGENXBIO during the second quarter worth $51,000. Legal & General Group Plc acquired a new position in REGENXBIO during the second quarter worth $56,000. Finally, Entropy Technologies LP purchased a new stake in shares of REGENXBIO in the first quarter valued at about $87,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Stock Performance

RGNX stock opened at $7.17 on Friday. The firm has a fifty day moving average price of $8.45 and a 200 day moving average price of $9.04. REGENXBIO has a fifty-two week low of $5.45 and a fifty-two week high of $16.19. The firm has a market cap of $473.29 million, a PE ratio of -1.89 and a beta of 1.13.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, August 6th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.35. The firm had revenue of $108.02 million for the quarter, compared to the consensus estimate of $97.63 million. REGENXBIO had a negative return on equity of 220.07% and a negative net margin of 112.58%. On average, equities analysts predict that REGENXBIO will post -3.70 EPS for the current year.

About REGENXBIO

REGENXBIO Inc (NASDAQ: RGNX) is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company’s programs use adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells, with the goal of addressing the underlying causes of disease rather than primarily treating symptoms.

REGENXBIO’s technology is built around its NAV AAV Technology Platform, which supports the design and development of gene-delivery vectors. Its pipeline has included investigational therapies for conditions such as Duchenne muscular dystrophy, Hunter syndrome, age-related macular degeneration and other rare diseases.